A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and tolerability of multiple doses of ALXN1210 (400 and 800
milligrams [mg]) following intravenous (IV) administration to healthy participants.